Skip to menu Skip to content Skip to footer
Professor David Johnson
Professor

David Johnson

Email: 
Phone: 
+61 7 3176 5050

Overview

Background

Professor David Johnson PSM

MB BS (Hons, Univ Medal), PhD (Syd), DMed(Res), FASN, FISN, FAHMS, FRACP

Department of Kidney and Transplant Services, Division of Medicine, Building 31, Princess Alexandra Hospital

david.johnson2@health.qld.gov.au

David Johnson is full-time Director of the Metro South Kidney and Transplant Service (MSKATS) and Medical Director of the Queensland Kidney Transplant Service (QKTS) at Princess Alexandra Hospital, Professor of Medicine and Professor of Population Health at University of Queensland, and Director of the Centre for Kidney Disease Research in Brisbane, Australia. He has a number of international leadership responsibilities, including Co-Chair of the International Society of Nephrology Global Kidney Health Atlas (ISN GKHA), Co-Chair of the International Society for Peritoneal Dialysis (ISPD) Guidelines on Peritonitis Prevention and Treatment, Co-Chair of the Global PDOPPS Steering Committee, Chair of SONG-PD, Immediate Past President of the Australian and New Zealand Society of Nephrology (ANZSN), Past President of the ISPD (2018-2020), Past Councillor of the ISN (2013-2019), and member of the ISN-ACT, ISN Research and ISN Monitor groups. He is currently a chair or member of 11 national and 7 international guideline groups and is ranked by Expertscape as the “top-rated expert in dialysis in the world during the years 2013-2023.” He has influenced policy and practice through his leadership as Deputy Chair of the Australian Better Evidence And Translation in Chronic Kidney Disease (BEAT-CKD) program, Deputy Chair of the Australasian Kidney Trials Network (AKTN), Chair of the Primary Healthcare Education Advisory Committee to Kidney Health Australia (PEAK), Co-Chair of the Australasian Creatinine and eGFR Consensus Working Party, Co-Chair of the Australasian Proteinuria Consensus Working Party, Member and Past-Chair of the ANZDATA Registry Peritoneal Dialysis Working Group, and Past-Chair of the Queensland Statewide Renal Clinical Network.

Having published over 1200 original manuscripts in peer-reviewed journals and presented over 550 abstracts at national and international scientific meetings, he brings critical expertise in designing and conducting multi-centre, multi-national randomised controlled trials (RCTs), developing national and international registries, using innovative research methodologies (such as registry-based RCTs) and implementing trial findings into practice. He has held lead roles in high-impact, large, multi-centre RCTs that have informed global clinical practice, including CKD-FIX, IDEAL, balANZ, HONEYPOT, TESTING, HERO, and IMPENDIA. He is currently principal investigator of the TEACH-PD and INCH-HD trials, and chair of the PHOSPHATE Trial Global Steering Committee. He helped establish the Australian Peritonitis Registry and led the highly successful National PD Peritonitis Quality Improvement Project, which reduced national peritonitis rates by two-thirds. He also led the universal implementation of automated laboratory reporting of eGFR in ANZ which increased national detection rates by 40%.

He has won numerous awards for both his basic science and clinical research science studies, including the ANZSN TJ Neale Award for “outstanding contributions to nephrologic science” (2005), the US National Kidney Foundation International Distinguished Medal (2014), the Canadian Society of Nephrology Dimitrios Oreopoulos Award (2017) and the Asia-Pacific Society of Nephrology Priscilla Kincaid-Smith Award (2021). He was a Queensland finalist in the Australian of the Year Awards in 2009 and was awarded a Public Service Medal by the Governor-General of Australia in 2011 for outstanding public service, particularly research into the early detection and management of kidney disease.

Availability

Professor David Johnson is:
Available for supervision

Fields of research

Qualifications

  • Doctoral Diploma, The University of Queensland

Research interests

  • Chronic kidney disease

  • Peritoneal dialysis

  • Haemodialysis

  • Kidney transplantation

Research impacts

Chronic kidney disease (CKD) is increasingly recognised as a major public health problem in Australia and worldwide. The Centre for Kidney Disease Research (CKDR) is one of Australia’s leading kidney disease research centres with an international reputation for excellence in research. The researchers of the CKDR are working at the forefront of global trends in research to understand the cellular and molecular basis of kidney disease and to trial innovative new clinical treatments to improve the health and well-being of people with kidney disease. Renowned for its studies in acute and chronic kidney disease and kidney cancers, the CKDR has particular expertise in translating results from laboratory and clinical sciences for application to improve public health outcomes.

The vision of our research program is to increase global equity in access to affordable, sustainable, quality kidney care. Some of the major achivements of the research program to date have been determining the ideal time to commence dialysis, the role of statins in improving cardiovascular outcomes in patients with kidney disease, biocompatible peritoneal dialysis fluid use, glucose-sparing peritoneal dialysis prescriptions for people with diabetes and kidney failure, mupirocin versus honey prophylaxis in peritoneal dialysis, anaemia treatment in chronic kidney disease, the role of allopurinol in preventing CKD progression, and the role of oral steroids in IgA nephropathy. A significant dataset has also been generated from the largest health survey conducted in the world (Global Kidney Health Atlas 2017, 2019, 2023). It is available to researchers globally, has informed WHO policy, underpinned advocacy activities to put kidney health on the international agenda; allowed benchmarking of progress for individual countries; enabled longitudinal evaluation of the organisation and structure of kidney care globally to inform policy, and has been used to facilitate policy changes and care strategies in international jurisdictions (Mexico, Caribbean, Fiji, Malaysia). The program has standardised practice and halved pertioneal dialysis-related infection. Implementation of multi-pronged strategies, now emulated by Canada and USA, led to establishment of a peritonitis registry, a national quality improvement program and publication of >50 papers on peritonitis, which influenced international PD guidelines. Highly cited and adopted internationally, the International Society for Pertioneal Dialysis (ISPD Guidelines) are considered the gold standard by other kidney care guideline groups. Finally, significant knowledge has been generated through the internationally endorsed Stanardised Outcomes in NephroloGy (SONG) initiative which uses shared priorities of patients, carers and clinicians to identify core outcome measures for kidney research. The ultimate result of the research program will be patient-prioritised research questions with outputs of critical importance to the global kidney care community that will inform international guidelines and policy, build capacity for international research collaboration and leadership, facilitate kidney care quality monitoring and reporting, and improve health outcomes for people with chronic kidney disease.

Works

Search Professor David Johnson’s works on UQ eSpace

1397 works between 1993 and 2025

1301 - 1320 of 1397 works

2003

Journal Article

Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations

Mcdonald, Stephen P., Collins, John F. and Johnson, David W. (2003). Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. Journal of The American Society of Nephrology, 14 (11), 2894-2901. doi: 10.1097/01.ASN.0000091587.55159.5F

Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations

2003

Journal Article

Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients

Johnson, David W., Nicol, David L., Preston, John M., Brown, Allison M., Hawley, Carmel M., Campbell, Scott B., Wall, Darryl, Griffin, Anthony D. and Isbel, Nicole M. (2003). Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients. Transplantation, 76 (3), 619-619. doi: 10.1097/01.TP.0000074314.46438.25

Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients

2003

Journal Article

A population-specific formula predicting creatinine excretion in continuous peritoneal dialysis (Letter to the Editor)

Rumpsfeld, M. and Johnson, D. W. (2003). A population-specific formula predicting creatinine excretion in continuous peritoneal dialysis (Letter to the Editor). Peritoneal Dialysis International, 23 (4), 406-408. doi: 10.1177/089686080302300419

A population-specific formula predicting creatinine excretion in continuous peritoneal dialysis (Letter to the Editor)

2003

Journal Article

Fibrogenic stresses activate different mitogen-activated protein kinase pathways in renal epithelial, endothelial or fibroblast cell populations

Pat, Betty K., Cuttle, Leila, Watters, Dianne, Yang, Tao, Johnson, David W. and Gobe, Glenda C. (2003). Fibrogenic stresses activate different mitogen-activated protein kinase pathways in renal epithelial, endothelial or fibroblast cell populations. Nephrology, 8 (4), 196-204. doi: 10.1046/j.1440-1797.2003.00162.x

Fibrogenic stresses activate different mitogen-activated protein kinase pathways in renal epithelial, endothelial or fibroblast cell populations

2003

Journal Article

Patient management by cyclosporine C2 monitoring: Not enough science yet to justify the practice (Letters to the Editor)

Campbell, Scott B. and Johnson, David W. (2003). Patient management by cyclosporine C2 monitoring: Not enough science yet to justify the practice (Letters to the Editor). Transplantation, 75 (11), 1917-1918. doi: 10.1097/01.TP.000065807.68596.16

Patient management by cyclosporine C2 monitoring: Not enough science yet to justify the practice (Letters to the Editor)

2003

Journal Article

Correlates of subclinical left ventricular dysfunction in ESRD

Fathi, Robert, Isbel, Nicole, Haluska, Brian, Case, Colin, Johnson, David W. and Marwick, Thomas H. (2003). Correlates of subclinical left ventricular dysfunction in ESRD. American Journal of Kidney Diseases, 41 (5), 1016-1025. doi: 10.1016/S0272-6386(03)00199-9

Correlates of subclinical left ventricular dysfunction in ESRD

2003

Journal Article

Clinicians' attitudes to clinical practice guidelines

Johnson, David W. (2003). Clinicians' attitudes to clinical practice guidelines. Medical Journal of Australia, 178 (7), 354-355.

Clinicians' attitudes to clinical practice guidelines

2003

Journal Article

A peritoneal dialysis patient with fatal culture-negative peritonitis

Johnson, David W., Gray, Nick and Snelling, Paul (2003). A peritoneal dialysis patient with fatal culture-negative peritonitis. Nephrology, 8 (1), 49-55. doi: 10.1046/j.1440-1797.2003.00119.x

A peritoneal dialysis patient with fatal culture-negative peritonitis

2003

Journal Article

Recommendations for the use of icodextrin in peritoneal dialysis patients

Johnson, David W., Agar, John, Collins, John, Disney, Alex, Harris, David C. H., Ibels, Lloyd, Irish, Ashley, Saltissi, David and Suranyi, Michael (2003). Recommendations for the use of icodextrin in peritoneal dialysis patients. Nephrology, 8 (1), 1-7. doi: 10.1046/j.1440-1797.2003.00117.x

Recommendations for the use of icodextrin in peritoneal dialysis patients

2003

Conference Publication

Renal cell carcinoma growth is regulated by autocrine insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) action

Cheung, C. W., Vesey, D. A., Nicol, D. L. and Johnson, D. W. (2003). Renal cell carcinoma growth is regulated by autocrine insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) action. 39th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth, Australia, 31 August - 3 September 2003. Carlton South, Australia: Blackwell Publishing Asia. doi: 10.1046/j.1440-1797.8.s3.1.x

Renal cell carcinoma growth is regulated by autocrine insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) action

2003

Book Chapter

Peritoneal dialysis

Johnson, David (2003). Peritoneal dialysis. Australia and New Zealand Dialysis and Transplant Registry: The 26th report 2003. (pp. 46-59) edited by Stephen McDonald and Graeme Russ. Adelaide, South Australia: ANZDATA Registry.

Peritoneal dialysis

2003

Journal Article

In vivo and in vitro models demonstrate a role for caveolin-1 in the pathogenesis of ischaemic acute renal failure

Mahmoudi, Mitra, Willgoss, Desley, Cuttle, Leila, Yang, Tao, Pat, Betty, Winterford, Clay, Endre, Zoltan, Johnson, David W. and Gobe, Glenda C. (2003). In vivo and in vitro models demonstrate a role for caveolin-1 in the pathogenesis of ischaemic acute renal failure. Journal of Pathology, 200 (3), 396-405. doi: 10.1002/path.1368

In vivo and in vitro models demonstrate a role for caveolin-1 in the pathogenesis of ischaemic acute renal failure

2003

Journal Article

Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation

Gill, D., Juffs, H. G., Herzig, K. A., Brown, A. M., Hawley, C. M., Cobcroft, R. G., Petrie, J. J., Marlton, P., Kennedy, G., Thomson, D. B., Campbell, S. B., Nicol, D. L., Norris, D. and Johnson, D. W. (2003). Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation. Transplantation Proceedings, 35 (1), 256-257. doi: 10.1016/S0041-1345(02)03796-X

Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation

2003

Conference Publication

A comparison of the fibrogenic effects of cisplatin, radiation, oxidative stress and TGF-B in an invitro model of renal fibrosis

Yang, T., Pat, B. K., Johnson, D., Wei, M. and Gobe, G. C. (2003). A comparison of the fibrogenic effects of cisplatin, radiation, oxidative stress and TGF-B in an invitro model of renal fibrosis. 39th Annual Scientific Meeting ANZ Society of Nephrology, Perth, 31 Aug - 3 Sep, 2003. Carlton South, Australia: Blackwell Publishing Asia.

A comparison of the fibrogenic effects of cisplatin, radiation, oxidative stress and TGF-B in an invitro model of renal fibrosis

2003

Conference Publication

Activation of protease-activated receptors (PAR) on cultured human proximal tubular cells (PAR) mediates inflammatory and fibroproliferative responses

Vesey, D. A., Cheung, C. W., Gobe, G. C. and Johnson, D. W. (2003). Activation of protease-activated receptors (PAR) on cultured human proximal tubular cells (PAR) mediates inflammatory and fibroproliferative responses. 39th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth, W. A., 31 August- 3 September, 2003. Carlton South, Australia: Blackwell Publishing Asia. doi: 10.1046/j.1440-1797.8.s3.1.x

Activation of protease-activated receptors (PAR) on cultured human proximal tubular cells (PAR) mediates inflammatory and fibroproliferative responses

2003

Conference Publication

Microarray gene expression analysis reveals role for JAK signaling pathway in oxidative stress-induced renal fibrosis

Pat, B. K., Tang, T., Watters, D., Johnson, D. W. and Gobe, G. C. (2003). Microarray gene expression analysis reveals role for JAK signaling pathway in oxidative stress-induced renal fibrosis. 39th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth, Western Australia, 1-3 September, 2003.

Microarray gene expression analysis reveals role for JAK signaling pathway in oxidative stress-induced renal fibrosis

2003

Conference Publication

Medicinal herbal extracts - treatment of renal disease

Gobe, G. C., Hoy, W. E., Wojcikowski, K., Myers, S. P. and Johnson, D. W. (2003). Medicinal herbal extracts - treatment of renal disease. Complementary and Alternative Therapies Symposium, Brisbane, Qld, Australia, 4-6 September, 2003.

Medicinal herbal extracts - treatment of renal disease

2003

Conference Publication

Activation of ERK in renal fibrosis after UUO stimulates epithelial proliferation and not fibroblast apoptosis

Pat, B. K., Yang, T., Watters, D., Johnson, D. and Gobe, G. C. (2003). Activation of ERK in renal fibrosis after UUO stimulates epithelial proliferation and not fibroblast apoptosis. 39th Annual Scientific Meeting ANZ Society of Nephrology, Perth, 31 Aug - 3 Sep, 2003. Carlton South, Australia: Blackwell Publishing Asia.

Activation of ERK in renal fibrosis after UUO stimulates epithelial proliferation and not fibroblast apoptosis

2003

Journal Article

Cost Savings from Peritoneal Dialysis Therapy Time Extension Using Icodextrin

Johnson, David W., Vincent, Kaia, Blizzard, Sophie, Rumpsfeld, Markus and Just, Paul (2003). Cost Savings from Peritoneal Dialysis Therapy Time Extension Using Icodextrin. Advances in Peritoneal Dialysis, 19, 81-85.

Cost Savings from Peritoneal Dialysis Therapy Time Extension Using Icodextrin

2003

Conference Publication

Thrombin stimulates inflammatory and fibro-proliferative responses in cultured human proximal tubule cells

Vesey, D. A., Cheung, C. W., Gobe, G. C. and Johnson, D. W. (2003). Thrombin stimulates inflammatory and fibro-proliferative responses in cultured human proximal tubule cells. 39th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth, W. A., 31 August- 3 September, 2003. Carlton South, Australia: Blackwell Publishing Asia. doi: 10.1046/j.1440-1797.8.s3.1.x

Thrombin stimulates inflammatory and fibro-proliferative responses in cultured human proximal tubule cells

Funding

Current funding

  • 2023 - 2028
    INCremental dialysis to improve Health in people starting HaemoDialysis (INCH-HD)
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2022 - 2028
    REMIT: An international, multi-centre, randomised clinical trial to compare treatment regimens in Primary Membranous Nephropathy (MRFF Grant administered by The University of Adelaide)
    University of Adelaide
    Open grant
  • 2021 - 2026
    Centre of Research Excellence: Partnering with patients with chronic kidney disease to transform care and outcomes (CRE-PACT) (administered by University of Sydney)
    University of Sydney
    Open grant
  • 2021 - 2025
    Pharmacy-based screening and quality use of medicines in kidney disease (MRFF Grant administered by The University of Sydney).
    University of Sydney
    Open grant
  • 2021 - 2025
    Increasing global equity in access to end-stage kidney disease care through better peritoneal dialysis affordability, practice, quality and outcomes
    NHMRC Investigator Grants
    Open grant
  • 2020 - 2027
    Implementation of Metformin theraPy to Ease DEcline of kidney function in PKD - the IMPEDE-PKD trial
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2020 - 2027
    Structured exercise program to reduce fatigue in patients receiving dialysis: a preference-stratified adaptive trial (M-FIT) (MRFF RCRDUN led by University of Sydney)
    University of Sydney
    Open grant
  • 2020 - 2025
    Teaching to improve health outcomes for peritoneal dialysis: The TEACH-PD Trial (HRC New Zealand)
    University of Otago
    Open grant
  • 2020 - 2025
    The GOAL Trial: Comprehensive geriatric assessment for frail older people with chronic kidney disease to increase attainment of patient-identified goals: A cluster randomised controlled trial
    NHMRC Targeted Research
    Open grant
  • 2019 - 2025
    The TEACH-PD study: a Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant

Past funding

  • 2022 - 2023
    A mixed-methods study to evaluate the trust and confidence in telehealth in chronic kidney disease
    University of Queensland In-kind/Indirect Funding
    Open grant
  • 2021 - 2023
    Patient perspectives and involvement in co-design of a trial evaluating interventions to improve gut health in peritoneal dialysis - GUT PD Study (ISPD grant led by Eastern Institute of Technology)
    Eastern Institute of Technology
    Open grant
  • 2021 - 2024
    Better Evidence and Translation In Chronic Kidney Disease (BEAT-CKD) (administered by SAHMRI)
    South Australian Health and Medical Research Institute Limited
    Open grant
  • 2019 - 2020
    PDOPPS ANZDATA Linkage Project.
    Fresenius Medical Care Australia Pty Ltd
    Open grant
  • 2019 - 2021
    A Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes - Cluster Randomised Controlled Trial (MSH Research Support Scheme Project Grant administered by MSHHS)
    Metro South Hospital and Health Service
    Open grant
  • 2018 - 2020
    IMPEDE-PKD (Implementation of Metformin therapy to Ease Decline of kidney function in PKD). A Clinical Trial Investigating Metformin to slow the progression of renal dysfunction in ADPKD
    PKD Foundation of Australia Limited
    Open grant
  • 2018 - 2020
    The TEACH-PD study: a Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes
    Metro South Hospital and Health Service
    Open grant
  • 2018 - 2022
    Targeted Education Approach to Improve Peritoneal Dialysis Outcomes (TEACH-PD) - A Cluster RCT
    Baxter Healthcare Pty Ltd
    Open grant
  • 2016 - 2019
    The TEACH-PD pilot Study
    Baxter Healthcare Pty Ltd
    Open grant
  • 2016 - 2021
    Better evidence, better care and outcomes for people with chronic kidney disease (NHMRC Program Grant administered by Flinders University)
    Flinders University
    Open grant
  • 2015 - 2019
    The CKD-FIX trial
    Waitemata District Health Board
    Open grant
  • 2015
    Understanding the role of lymph node stromal microenvironment in renal cell carcinoma progression: Phase 2 - identifying personalized therapeutic strategies
    UQ-Ochsner Seed Fund for Collaborative Research - DVCR funds
    Open grant
  • 2014 - 2021
    Evaluation of the integrated home dialysis
    Baxter Healthcare Pty Ltd
    Open grant
  • 2014 - 2018
    The Australian Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)
    NHMRC Project Grant
    Open grant
  • 2013 - 2019
    Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase (CKD-FIX): A double-blind, randomised, placebo-controlled trial
    NHMRC Project Grant
    Open grant
  • 2013 - 2017
    The SIGNAL Trial: Steroids in ImmunoGlobulin A Nephropathy: Assessment of Long term outcomes (NHMRC Project Grant administered by University of Sydney)
    University of Sydney
    Open grant
  • 2012 - 2013
    The utility of matrix metalloproteinase-2 (MMP-2) to predict peritoneal injury in the incident PD population
    Kidney Health Australia
    Open grant
  • 2012 - 2014
    Serial NT-proBNP Monitoring for Predicting Major Cardiovascular Events in the Dialysis Population
    NHMRC Project Grant
    Open grant
  • 2011 - 2015
    A randomised, placebo-controlled trial of Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia in chronic kidney disease
    NHMRC Project Grant
    Open grant
  • 2011 - 2013
    Macrophages: A therapeutic target in peritoneal dialysis-induced fibrosis? (NHMRC Project Grant administered by Wesley Research Institute)
    Wesley Merdical Research
    Open grant
  • 2010 - 2013
    Enhancing erythropoietin therapy in ischaemia-reperfusion injury of heart and kidney
    NHMRC Project Grant
    Open grant
  • 2008 - 2011
    A randomised, placebo-controlled trial of oxpentifylline on haemoglobin levels in patients with erythropoietin-resistant anaemia
    AMGEN Australia Pty. Ltd.
    Open grant
  • 2008 - 2013
    HONEYPOT (A randomized controlled trial evaluation of antibacterial HOney versus Nasal Eradication of staphYlococci for the Prevention Of Tenckhoff infections in PD)
    Baxter Healthcare Pty Ltd
    Open grant
  • 2007 - 2010
    HERO (A randomized, placebo-controlled trial of oxpentifylline on haemoglobin levels in patients with erythropoietin-resistant anaemia)
    Janssen-Cilag Pty Limited (Janssen-Cilag Australia)
    Open grant
  • 2006 - 2009
    Cytoprotection by erythropoietin in hypoxia-ischaemia of the kidney and brain
    NHMRC Project Grant
    Open grant
  • 2005 - 2016
    Australasian Kidney Trials Network (AKTN)
    NHMRC Enabling Grant
    Open grant
  • 2005 - 2011
    Australasian Clinical Trials Network in Nephrology (CTNN)
    Australian Kidney Foundation
    Open grant
  • 2003 - 2005
    Causes, assessment and treatment of dehydration in older people.
    NHMRCARC Ageing Well, Ageing Productively Program
    Open grant
  • 2003 - 2007
    Centre of Clinical Research Excellence in Cardiovascular Disease and Metabolic Disorders
    NHMRC Research Centre Grant
    Open grant
  • 2002
    Strategies for targeted renal delivery of viral vectors for controlled and long-term gene therapy against chronic renal failure
    University of Queensland Research Development Grants Scheme
    Open grant
  • 2001 - 2002
    Applying anti-apoptotic benefits of BCL-XL in the ischaemia-reperfusion injured kidney
    Mayne Bequest Fund
    Open grant
  • 2000 - 2002
    Effects of risk factor control on atherosclerosis, vasoreactivity and cardiac ischemia in patients on dialysis
    NHMRC Project - Priming Grant
    Open grant

Supervision

Availability

Professor David Johnson is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Professor David Johnson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au